EPISODE · Sep 17, 2025 · 11 MIN
MindMed: Rethinking brain health with psychedelic therapy
Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and strong financial backing. CEO Rob Barrow outlines the company's ambitious goals and the path to potentially transforming mental healthcare at RBC's Global Healthcare Conference.
Embed this episode
NOW PLAYING
MindMed: Rethinking brain health with psychedelic therapy
0:00
11:58
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Pathfinders in Biopharma?
This episode is 11 minutes long.
When was this Pathfinders in Biopharma episode published?
This episode was published on September 17, 2025.
Can I download this Pathfinders in Biopharma episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!